Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-23
2010-12-28
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S453000, C548S525000, C549S276000
Reexamination Certificate
active
07858657
ABSTRACT:
Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
REFERENCES:
patent: 3668222 (1972-06-01), Hauser
patent: 4636195 (1987-01-01), Wolinsky
patent: 5480906 (1996-01-01), Creemer et al.
patent: 5602278 (1997-02-01), Kirkpatrick
patent: 6703414 (2004-03-01), Powis et al.
patent: 7081475 (2006-07-01), Powis et al.
patent: 7446124 (2008-11-01), Kirkpatrick et al.
patent: 2003/0109572 (2003-06-01), Powis
patent: 2006/0063824 (2006-03-01), Kirkpatrick et al.
patent: 2006/0128793 (2006-06-01), Zask et al.
patent: 2006/0167080 (2006-07-01), Powis et al.
patent: 0658343 (1995-06-01), None
patent: 1435941 (2006-08-01), None
patent: 1686124 (2006-08-01), None
patent: 2 302 021 (1997-01-01), None
patent: 2302021 (1997-01-01), None
patent: WO 90/01969 (1990-03-01), None
patent: WO 90/03768 (1990-04-01), None
patent: WO 03/024183 (2003-03-01), None
patent: WO 2006/044453 (2006-04-01), None
patent: WO 2007/008200 (2007-01-01), None
Wipf et al., Org. Biomol. Chem. (2004), vol. 2, pp. 1911-1920 (published on the Web Jun. 14, 2004).
Norman et al., J. Med. Chem. (1996), vol. 39, pp. 1106-1111.
Submitted to applicant in parent U.S. Appl. No. 11/178,553.
Ciardiello et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Late Stage Clinical Trials, 2003, Expert Opinion on Emerging Drugs, 8(2):501-514.
Sorensen et al, Paclitaxel, Gemcitabine, and Cisplatin in Non-resectable Non-small-cell Lung Cancer, 1999, Annals of Oncology, 10(9):1043-1049.
Kirkpatrick et al. Antitumor Activity, Pharmacodynamics and Toxicity of PX-866 a Novel Inhibitor of Phosphoinositide-3-kinase, 2004, European Journal of Cancer, 2(8): 77.
Ihle et al. Molecular Pharmacology and Antitumor Activity of PX-866, a Novel Inhibitor of Phosphoinositide-3-kinase Signaling, 2004, Molecular Cancer Therapeutics, 3(7):763-772.
Brevis et al., Faranoxi-A New Antitumor Agent, 1996, J. Chemo. 8(1):67-69.
Zalgeviciene et al., Embryotoxicity and Teratogenicity of Some Derivatives of Chloroethylaminophenylacetic Acid, 1998, Pathology Oncol. Res. 4(1):27-29.
Haefliger et al., Selektive Funktionalisierung von Wortmannin mit Hilfe einer Furanring-Maskierung, 1975, Helvetia Chimica Acta 58(6):Nr. 179-180, pp. 1620-1628.
Norman et al., Studies on the Mechanism of Phosphatidylinositol 3-Kinase Inhibition by Wortmannin and Related Analogs, 1996, J. Med. Chem. 39:1106-1111.
Langer, New Methods of Drug Delivery, 1990, Science 249:1527-1533.
Mathiowitz et al., Photochemical Rupture of Microcapsules: A Model System, 1981, J. App. Poly. Sci. 26:809-822.
Kohn, Current Trends in the Development of Synthetic Materials for Medical Applications, 1990, Pharmaceutical Technology, 14(10):32-41.
Folch et al., A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues, 1957, J. Biol. Chem. 226:497-509.
Clarke et al., AlkalineO→N-transacylation: A New Method for the Quantitative Deacylation of Phospholipids, 1981, BioChem. J. 195:301-306.
Auger et al., Separation of Novel Polyphosphoinositides, 1990, Methods in Inositide Research, pp. 159-166, Irvine ed., Raven Press Ltd., New York, NY.
Lala et al., Role of Nitric and Oxide in Tumor Progression: Lessons from Experimental Tumors, 1998, Cancer and Metastasis Reviews 17(1):91-106.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, 1999, Science 286:531-537.
Wipf et al., Synthesis and Biological Evaluation of Synthetic Viridins Derived from C(20)-Heteroalkylation of the Steroidal PI-3-Kinase Inhibitor Wortmannin, 2004, Org. Biomol. Chem. 2:1911-1920.
Kirkpatrick Lynn D.
Powis Garth
Wipf Peter
Arizona Board of Regents, Acting on Behalf of The University of
Proix Pharmaceutical Corp.
Solola Taofiq A
University of Pittsburgh - Of the Commonwealth System of Higher
Wilson Sonsini Goodrich & Rosati
LandOfFree
Wortmannin analogs and methods of using same in combination... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Wortmannin analogs and methods of using same in combination..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wortmannin analogs and methods of using same in combination... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4231402